| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Jun―27 |
Unveiling the silent threat: COVID-19 and myocardial injury |
Ke Xu, Wu He, Bo Yu, James Jiqi Wang, Junfang Wu, Dao Wen Wang |
| 2 |
[GO] |
2022―Feb―02 |
Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences |
Kimiyasu Shiraki, Noriaki Sato, Kaoru Sakai, Shirou Matsumoto, Richard H. Kaszynski, Masaya Takemoto |
| 3 |
[GO] |
2021―Okt―28 |
Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2 |
Brian F. Niemeyer, Kambez H. Benam |
| 4 |
[GO] |
2021―Jun―23 |
Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions |
Marcel Renn, Eva Bartok, Thomas Zillinger, Gunther Hartmann, Rayk Behrendt |
| 5 |
[GO] |
2021―Jun―23 |
Drug repurposing for COVID-19: Approaches, challenges and promising candidates |
Yan Ling Ng, Cyrill Kafi Salim, Justin Jang Hann Chu |
| 6 |
[GO] |
2021―Mrz―01 |
SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin |
Saeed Mehrzadi, Mohammad Yahya Karimi, Alireza Fatemi, Russel J. Reiter, Azam Hosseinzadeh |
| 7 |
[GO] |
2020―Dez―01 |
A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor |
Murat Oz, Dietrich Ernst Lorke, Nadine Kabbani |
| 8 |
[GO] |
2020―Nov―11 |
Treating exuberant, non-resolving inflammation in the lung; implications for acute respiratory distress syndrome and COVID-19 |
Derek W. Gilroy, Roel P.H. De Maeyer, Mark Tepper, Alastair O’Brien, Mohib Uddin, Judy Chen, et al. (+2) Daniel R. Goldstein, Arne N. Akbar |
| 9 |
[GO] |
2020―Okt―16 |
Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing |
Yolanda Augustin, Henry Staines, Sanjeev Krishna |
| 10 |
[GO] |
2020―Okt―05 |
Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications? |
Ahmed M. Darwesh, Wesam Bassiouni, Deanna K. Sosnowski, John M. Seubert |
| 11 |
[GO] |
2020―Sep―08 |
Chloroquine and Hydroxychloroquine in the Treatment of Malaria and Repurposing in Treating COVID-19 |
Zi-Ning Lei, Zhuo-Xun Wu, Shaowei Dong, Dong-Hua Yang, Litu Zhang, Zunfu Ke, et al. (+2) Chang Zou, Zhe-Sheng Chen |
| 12 |
[GO] |
2020―Jul―09 |
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities |
James Jiqi Wang, Matthew L. Edin, Darryl C. Zeldin, Chenze Li, Dao Wen Wang, Chen Chen |
| 13 |
[GO] |
2020―Jun―24 |
Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? |
Christian Bailly, Gérard Vergoten |
| 14 |
[GO] |
2020―Mai―27 |
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients |
Tianxiao Liu, Songyuan Luo, Peter Libby, Guo-Ping Shi |
